Intelligence Feed event · Policy · 2026-09-24

    HUTCHMED and AstraZeneca to Present Savolitinib Phase III NSCLC Data at ESMO

    Question

    HUTCHMED and AstraZeneca to Present Savolitinib Phase III NSCLC Data at ESMO

    Direct answer

    HUTCHMED and development partner AstraZeneca are set to unveil full Phase III clinical data for the savolitinib plus osimertinib combination in NSCLC at the ESMO Congress 2026 in Madrid. The presentations encompass the global SAFFRON study and China-focused SANOVO study, both of which reached statistically significant outcomes in targeting MET-amplified, EGFR-mutated non-small cell lung cancer.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-24
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “HUTCHMED and AstraZeneca to Present Savolitinib Phase III NSCLC Data at ESMO”, revision 1, evidence through 2026-09-24. https://marketontology.com/market-events/2026-09-24/hutchmed-and-astrazeneca-to-present-savolitinib-phase-iii-nsclc-data-at-esmo-6bce60

    POLICY
    HUTCHMED and AstraZeneca to Present Savolitinib Phase III NSCLC Data at ESMO
    HUTCHMED and development partner AstraZeneca are set to unveil full Phase III clinical data for the savolitinib plus osimertinib combination in NSCLC at the ESMO Congress 2026 in Madrid. The presentations encompass the global SAFFRON study and China-focused SANOVO study, both of which reached statistically significant outcomes in targeting MET-amplified, EGFR-mutated non-small cell lung cancer.
    HCMAZN
    Impact
    69
    SEP 24
    SIG
    85%
    HCMAZN
    HUTCHMED and AstraZeneca to Present Savolitinib Phase III NSCLC Data at ESMO
    HUTCHMED and development partner AstraZeneca are set to unveil full Phase III clinical data for the savolitinib plus osimertinib combination in NSCLC at the ESMO Congress 2026 in Madrid. The presentations encompass the global SAFFRON study and China-focused SANOVO study, both of which reached statistically significant outcomes in targeting MET-amplified, EGFR-mutated non-small cell lung cancer.
    → Positive Phase III SAFFRON data presentation at ESMO validates AstraZeneca and HUTCHMED's combination regimen for Tagrisso-resistant NSCLC, expanding peak sales potential.
    Impact
    HUTCHMED and development partner AstraZeneca are set to unveil full Phase III clinical data for the savolitinib plus osimertinib combination in NSCLC at the ESMO Congress 2026 in Madrid. The presentations encompass the global SAFFRON study and China-focused SANOVO study, both of which reached statistically significant outcomes in targeting MET-amplified, EGFR-mutated non-small cell lung cancer.
    Affected
    HCMAZN
    Transmission
    Positive Phase III SAFFRON data presentation at ESMO validates AstraZeneca and HUTCHMED's combination regimen for Tagrisso-resistant NSCLC, expanding peak sales potential.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    HCMmilestone and royalty monetization via AstraZeneca partnershipUp1-4wSource confirms Phase III SAFFRON and SANOVO data presentations scheduled for ESMO 2026.
    AZNline extension for Tagrisso oncology franchiseUp1-4wAstraZeneca partners with HUTCHMED on savolitinib/osimertinib combination regimens.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    HCMUpagreed13.90 2026-09-24+0.29%+4.82%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month